Download Files:
JNJ-42226314
$350 – $2,450
Products Details
Product Description
– JNJ-42226314 is a competitive, highly selective and reversible non-covalent monoacylglycerol lipase (MAGL) inhibitor. JNJ-42226314 demonstrates dose-dependent enhancement of the major endocannabinoid 2-arachidonoylglycerol (2-AG) as well as efficacy in models of neuropathic and inflammatory pain[1].
Web ID
– HY-133130
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Neuroscience-Neuromodulation
Molecular Formula
– C26H24FN5O2S
References
– [1]Wyatt RM, et al.Pharmacologic characterization of JNJ-42226314, [1-(4-fluorophenyl)indol-5-yl]-[3-[4-(thiazole-2-carbonyl)piperazin-1-yl]azetidin-1-yl]methanone, a reversible, selective and potent monoacylglycerol lipase inhibitor.J Pharmacol Exp Ther. 2019 Dec 9.
CAS Number
– 1252765-13-1
Molecular Weight
– 489.56
Compound Purity
– 99.47
SMILES
– O=C(N1CCN(C2CN(C(C3=CC4=C(N(C5=CC=C(F)C=C5)C=C4)C=C3)=O)C2)CC1)C6=NC=CS6
Clinical Information
– No Development Reported
Research Area
– Neurological Disease
Solubility
– DMSO : 250 mg/mL (ultrasonic)
Target
– MAGL
Pathway
– Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
